Can You Train With Costochondritis? The Chest-Wall Audit: Where the Michigan Primary-Care Census of 399 Episodes Priced Musculoskeletal Chest Pain at 20.4% Plus Costochondritis at 13.1% Against Reflux's 13.4%, Where the New York ED Census Found the Condition in 30% of 122 Non-Traumatic Chest-Pain Patients With Women at 69% of the Group, Where the JAMA History Review Ran Palpation-Reproducible Pain at a Likelihood Ratio of 0.2–0.3 for Acute Coronary Syndromes While Coronary Disease Still Sat in 3–6% of Tenderness-Positive Adults and Myocardial Infarction Inside 6% of the Costochondritis Group Itself, Where the One-Year Follow-Up Kept 55% Still Reporting Chest Pain With Only a Third Still Definite, Where the Family's Only Randomized Trial (Tietze, 40 Patients) Improved Pain 65.4% vs 46.7% at Three Weeks While the Swelling Stayed Put at 10% vs 5%, Where the Fibromyalgia Acquittal Ran 8% Against Widespread Pain at 42%, and Where the Brazilian ACCEPT Registry Counted 5,047 Acute-Coronary Patients Across 47 Hospitals With 13.6% One-Year Events: Get the Heart Ruled Out First, Then Train Everything the Rib Joints Don't Own

There is a fence at the top of this post and in this file it is taller than in any other file the injury family has opened: chest pain is the one complaint where the heart outranks the program, always, before the first set is discussed — pain that arrives with exertion and leaves with rest, radiates to one or both shoulders or arms, or travels with shortness of breath, sweating, nausea or a racing irregular pulse is the emergency-department door, now, not a mobility drill [4][5]. The second fence, the one this whole file turns on: "reproducible by palpation" is the strongest single benign feature the chest-pain history carries — a likelihood ratio of 0.2–0.3 for acute coronary syndromes — and it is not a pass: coronary artery disease sits in 3 to 6% of adults whose chest pain reproduces with chest-wall palpation [4][5], and in the emergency-department census that anchors this audit, 6% of the costochondritis group itself was having an acute myocardial infarction at the same time [1]. The third fence: the naming is not the lifter's job — the review is explicit that patients older than 35, anyone with cardiac risk factors, and any cardiopulmonary symptom get an ECG (and possibly a chest radiograph) before the benign chest wall gets its name [5]. And the fence has a local address: in the Brazilian registry that anchors this app's home market, 5,047 patients hospitalized with acute coronary syndromes across 47 hospitals suffered 13.6% major cardiovascular events within one year — the door this file fences against is an everyday admission in Brazilian cardiology, not a theoretical risk [10][11]. With the fences respected, the question underneath is the gym's most panicked quiet question: the shutdown script ("chest pain = heart = no lifting, maybe forever") versus the self-diagnosis script ("it's just the rib joints, push through"). Both scripts are wrong in opposite directions, and the audit gives each its correction.

The short answer: yes — after the heart has been ruled out, train everything the rib joints don't own

Strip the file to its spine. Chest-wall pain is the most common named thing chest pain turns out to be: in the Michigan primary-care network's prospective census of 399 episodes, musculoskeletal chest pain led all diagnoses at 20.4%, with costochondritis separately at 13.1% — against reflux esophagitis's 13.4% — at an average of 1.53 visits per episode [2]. In the emergency-department census, 30% of 122 consecutive non-traumatic chest-pain patients had costochondritis [1]. In children, the same shape: of 407 pediatric emergency visits, musculoskeletal causes ran 15% and idiopathic 21% against cardiac at 4%, with chest-wall tenderness the single most common physical finding [3]. The palpation paradox is the file's engine: the JAMA review of the chest-pain history pooled the evidence that stabbing, pleuritic, positional, or palpation-reproducible pain runs likelihood ratios of 0.2–0.3 for acute coronary syndrome — while radiation to the shoulders or arms and exertional precipitation run it up [4]; the family-medicine review answers with the coexistence number — 3–6% coronary disease in tenderness-positive adults — and the ED census closes the loop with infarction inside 6% of its costochondritis group [1][5]. The natural history is benign and slower than the internet promises: at one year, 55% of the followed costochondritis patients still reported chest pain, but only a third still had definite costochondritis — resolution is the tendency, not a deadline [1]. The treatment file is priced at its true thinness: "clinical trials of treatment are lacking" is the review's own sentence — acetaminophen or NSAIDs where safe, avoiding activities that produce chest-muscle overuse, and reassurance [5]; the only randomized trial in the family is Tietze's 40-patient prednisolone trial, where pain and quality of life improved markedly while the visible swelling did not (10% vs 5%, not significant) — treat pain and function, not the swelling [7]. The program is the treatment: the same review that says trials are lacking prescribes chest-muscle-overuse avoidance — a dose modification, not a shutdown — and the anatomy review explains why the chest-wall file often answers to the neck-and-shoulder program one door up [5][6]. The verdict writes itself: rule the heart out first (ECG if over 35 or any risk — the fence), then train legs, lungs and everything the rib joints don't own at full dose, dose the pressing down to what the sternum tolerates, and grade the comeback by next-morning response, not by calendar.

Who is asking: the census file

Start with who actually carries this file, because the fear imagines a middle-aged man clutching his chest mid-set, while the census files a different picture. The primary-care census — 399 complete episodes collected prospectively across the Michigan Research Network's urban, rural, academic and private sites — is the calmest number in this audit: musculoskeletal chest pain at 20.4% of all diagnoses, reflux esophagitis at 13.4%, costochondritis at 13.1%, the whole workup averaging 1.53 visits [2]. The emergency-department census sharpens it: of 122 consecutive patients with non-traumatic chest pain, 36 (30%) had costochondritis — and the group ran 69% women against 31% in the non-costochondritis controls, with Hispanic patients at 47% against 24% [1]. The pediatric census completes the age sweep: 407 children evaluated prospectively, idiopathic causes leading at 21%, musculoskeletal at 15%, cardiac at just 4% — with chest-wall tenderness the most common abnormality on examination, 43% of the pain acute under 48 hours, 7% chronic beyond six months, and a testing lesson worth quoting to every anxious parent-lifter: ECGs were obtained in 47% of the children, 31 of 191 were abnormal, and only 4 of those 191 abnormalities had anything to do with the final diagnosis [3]. Three settings, one shape: the chest wall is the most common named tenant of the chest-pain file, the heart is the rarest — and the distance between those two frequencies is exactly the space a calm program fills. This is the same shape the library found in its ankle and wrist files: a common, mechanical, self-limiting condition that fear misprices as a catastrophe.

The palpation paradox: the strongest benign sign that never clears the heart

Every lifter who has pressed a thumb into a sore sternum and felt the exact pain light up knows the move this section has to price. The JAMA systematic review of the chest-pain history did the pooling: pain that is stabbing, pleuritic, positional, or reproducible by palpation decreases the likelihood of acute coronary syndrome and infarction with likelihood ratios of 0.2–0.3 — genuinely, one of the strongest probability-shifting features the history carries in either direction [4]. But a likelihood ratio of 0.2–0.3 is not zero, and the review's own framing is "value and limitations": the same chest that reproduces with a thumb can carry a plaque [4]. The family-medicine review put the number on it: coronary artery disease is present in 3 to 6 percent of adult patients whose chest pain and tenderness reproduce with palpation — which is why its algorithm gives history and physical the diagnostic lead only in children, adolescents and young adults, and routes anyone over 35, anyone with cardiac history or risk, and any cardiopulmonary symptom to the ECG, with a chest radiograph where indicated [5]. The emergency-department census supplies the closing exhibit: 6% of its costochondritis group was experiencing an acute myocardial infarction — lower than the 28% of the non-costochondritis controls, exactly the direction the likelihood ratio predicts, and nowhere near zero [1]. The gym translation is a two-line rule: tenderness that reproduces the pain makes the chest-wall file more likely — and earns you a faster ECG, not a skipped one. The program does not start until that ECG has been done or the age-and-risk file has genuinely cleared you.

The Brazil fence: why the cardiac door is not an abstraction here

This app's home market gives the fence its local weight. The ACCEPT registry — the Brazilian multicenter prospective cohort of acute coronary syndromes — enrolled 5,047 patients hospitalized across 47 Brazilian hospitals between 2010 and 2014; ST-elevation infarction was the most frequent diagnosis at 35.8%; and 13.6% suffered a major cardiovascular event (cardiovascular death, reinfarction, or stroke) within one year, with adherence to evidence-based therapy at admission running 62.1% [10]. The interior column of the same fence: the Uberaba (Minas Gerais) federal-university tertiary-center cohort — 79 acute-coronary patients treated with percutaneous intervention between March and September 2024, 67% of them men — the door's plainest everyday form outside the capitals [11]. These are the numbers that make the pt-BR lane of this post read differently from a generic reassurance piece: in the very population most likely to Google "dor no peito depois do treino," the cardiac file is a leading actor, and the 28% infarction rate in the census's non-costochondritis group is the quarter of the chest-pain file this post is not [1][10][11]. The honest order of operations for the Brazilian lifter is therefore identical to the American one and worth saying in one sentence each language: primeiro o ECG, depois a academia — the ECG first, the gym second [5][10].

Tietze, the swollen twin, and the myofascial door

Two names travel together in this file and the distinction matters for training decisions. Costochondritis — the tenderness without swelling, often multiple junctions, the 30% of the ED census — is this file's main tenant [1][5]. Tietze syndrome is the rarer twin with visible swelling: the Bahia-authored review frames it as a benign, self-limiting joint disease of the sternocostal, sternoclavicular or costochondral joints, of unknown cause though microtrauma is the standing suspect, diagnosed by palpation tenderness with laboratory and imaging support, treated conservatively first — analgesics and NSAIDs — with corticosteroid infiltration reserved for resistant cases [9]. The training translation: the swollen joint is the same train-around file with one extra rule — a hot, swollen, single sternoclavicular joint that wakes you at night or comes with fever is a clinician visit (its differential explicitly includes the coronary syndrome, and infection and inflammation belong to the doctor's exam, not the lifter's) [9]. The third door the anatomy review opens is the one experienced lifters will recognize before the literature does: noncardiac chest pain runs a myofascial continuum through the upper quadrant — the fascial connections between neck, chest wall and upper limb mean a chest that hurts to press is often reporting a neck-and-shoulder file, with spinal dysfunction, costochondritis, Tietze and slipping ribs listed as the mechanical family and reflux as the most common noncardiac cause overall [6]. That is why the program below borrows from the library's shoulder-impingement and neck files as much as from any chest source: the chest wall is wired into the same chain the rowing and thoracic-mobility work already serves [6].

The natural-history honesty: benign, common, and slower than the internet promises

The reassurance file needs its own audit, because "self-limiting" is true in direction and misleading as a deadline. The emergency-department census followed its costochondritis group out one year: of the patients reachable at follow-up, 55% still reported chest pain — but only about a third still had definite costochondritis on re-examination [1]. Read that twice, because it holds both the reassurance and the patience tax: the joint file itself resolves in most, the symptom file can linger, and neither number contains a catastrophe [1]. The review's framing is the same: usually self-limited and benign, distinguished from more serious causes precisely so that the reassurance is earned rather than assumed [5]. The Tietze review agrees in its own language — benign and self-limiting — and the pediatric census adds the timeline parents and young lifters actually need: acute presentation in 43%, chronic beyond six months in 7%, and 30% of the children missed school over it — the symptom is real even when the file is benign [3][9]. For programming, this natural history sets expectations honestly: this is a weeks-to-months joint file managed like the library's tendinopathy audits — dose-modified, tolerance-graded, tracked — not a seven-day interruption with a clean return date [1][5].

The treatment file priced at its true thinness — and what the only RCT actually showed

Honesty about the evidence is this file's signature move, because the treatment literature is thin enough to read in an afternoon. The family-medicine review states it plainly: "clinical trials of treatment are lacking" — the traditional prescription is acetaminophen or anti-inflammatory medication where safe and appropriate, avoidance of the activities that produce chest-muscle overuse, and reassurance [5]. The one randomized trial in the family is the Tietze trial from Cairo: 40 patients, a three-week oral prednisolone taper (40 mg → 20 mg → 10 mg) plus NSAIDs versus NSAIDs alone — pain scores fell 46.8% vs 17.7% at week one and 65.4% vs 46.7% at week three, both P<.001, with the 25.8-point percent difference maintained at a median 6.5 months, and quality-of-life scores favoring the steroid arm (median 7 vs 10, P<.001) [7]. The trial's sharpest finding is not the pain number but the swelling one: obvious joint-swelling improvement at three weeks ran 10% versus 5%, not significant — pain and quality of life moved while the visible swelling stayed [7]. The lesson generalizes to the unswollen twin this file is about: treat and track pain and function, not the lump [7]. The injection shelf is priced to match: the prolotherapy series — 21 Tietze patients against 13 on NSAIDs, unblinded — reported visual-analog pain falling from about 7.1 to 1.5 across three injections against 7.1 to 2.6 on medication, faster recovery at P=.001, which is promising and small and unblinded, in that order [8]. And a cross-reference the library already filed: if the anti-inflammatory route is your plan, read what the painkillers audit says about training on NSAIDs before you make it a habit [5]. The fibromyalgia acquittal closes the treatment section where the census opened it: only 8% of the ED costochondritis group met fibromyalgia criteria, though widespread pain ran 42% versus 5% of controls — the chest-wall file is overwhelmingly its own local condition, not the tip of a systemic iceberg, which is exactly why local dose management works [1].

The program: dose the joint, don't shut down the lifter

With the heart cleared and the chest wall named, the program writes itself from the same logic every file in this family runs — train around, dose the provoking structure, grade by response. What trains at full dose from day one, every path: the legs (squats, hinges, unilateral work — a healthy sternum is not required to squat or deadlift), the trunk, the back (rows and pulls are usually the best-tolerated upper-body work this file owns — they open the chest and serve the myofascial chain the anatomy review describes), and every conditioning modality that doesn't reproduce the pain [5][6]. What gets dosed down: the pressing family that loads the costochondral and chondrosternal junctions — barbell bench, deep dips, flyes and cable crossovers into the stretched position, and loaded end-range pec work are the structures' chief customers; the review's phrase is the programming rule: avoid the activities that produce chest-muscle overuse, temporarily — a deload aimed at a joint instead of the nervous system [5]. The practical substitutions the shoulder and pec files already popularized work here: floor pressing and board/block presses that stop short of the stretched position, landmine presses, shallower dip depths, higher-rep lighter-load pressing that keeps the sternum quiet — provocation is the dose meter, not the exercise name [5]. What stops until cleared: the cardiac-pattern signs from the top of this file — exertional reproduction, radiating pain, breathlessness, sweating — and any hot, swollen, night-waking or feverish joint [4][5][9]. What the analgesic shelf is: short-course acetaminophen or NSAIDs where safe, per the review, with the painkillers-audit caveat on chronic NSAID use while training [5]. And through all of it, track the work: with a one-year file this long, response-against-dose is the only honest progress column — the same next-morning rule the train-when-sore audit grades everything else by [1][5].

The bottom line

• The census: 20.4% musculoskeletal + 13.1% costochondritis of 399 primary-care episodes against reflux's 13.4%; 30% of 122 ED chest-pain patients; in children, musculoskeletal 15% + idiopathic 21% against cardiac 4% — the chest wall is the most common named tenant of the chest-pain file [1][2][3].
• The palpation paradox: reproducible-by-palpation pain runs LR 0.2–0.3 for acute coronary syndromes — and coronary disease sits in 3–6% of tenderness-positive adults, with infarction inside 6% of the costochondritis group itself [1][4][5].
• The fence outranks the program: over 35, cardiac risk, or any cardiopulmonary symptom = ECG before the gym talk; exertional, radiating, or sweat-and-breath pain = the emergency department now [4][5].
• The Brazil anchors: ACCEPT's 5,047 patients across 47 hospitals with 13.6% one-year major events; Uberaba's 79-patient interior cohort — primeiro o ECG, depois a academia [10][11].
• The natural history: 55% still reporting chest pain at one year, but only a third still definite costochondritis — benign in direction, patient in timeline [1].
• The treatment file: trials lacking — analgesics where safe, chest-muscle-overuse avoidance, reassurance [5]; the only RCT (Tietze, 40 patients) moved pain 65.4% vs 46.7% and quality of life while the swelling stayed put at 10% vs 5% — treat pain and function, not the lump [7]; the prolotherapy series is promising, small, unblinded, in that order [8].
• The fibromyalgia acquittal: 8% criteria-positive against 42% widespread pain — a local joint file, which is why local dose management works [1].
• The myofascial door: the chest wall is wired into the neck–shoulder–upper-limb chain — the rows and thoracic work were already the treatment [6].

Get the heart ruled out first, then train everything the rib joints don't own — the pressing doses down to what the sternum tolerates, the comeback answers to next-morning response rather than calendar, and the file closes with evidence instead of panic at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

1. Disla E, Rhim HR, Reddy A, Karten I, Taranta A. Costochondritis. A prospective analysis in an emergency department setting. Archives of Internal Medicine, 1994;154(21):2466–2469. pubmed.ncbi.nlm.nih.gov
2. Klinkman MS, Stevens D, Gorenflo DW. Episodes of care for chest pain: a preliminary report from MIRNET. Michigan Research Network. The Journal of Family Practice, 1994;38(4):345–352. pubmed.ncbi.nlm.nih.gov
3. Selbst SM, Ruddy RM, Clark BJ, et al. Chest pain in children. A prospective study. Pediatrics, 1988;82(3):319–323. pubmed.ncbi.nlm.nih.gov
4. Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA, 2005;294(20):2623–2629. pubmed.ncbi.nlm.nih.gov
5. Proulx AM, Zryd TW. Costochondritis: diagnosis and treatment. American Family Physician, 2009;80(6):617–620. pubmed.ncbi.nlm.nih.gov
6. Raja GP, Punja R, Cruz AM, Prabhu A. The myofascial continuum: anatomical insights into noncardiac chest pain. Clinical Anatomy, 2026;39(1):2–8. pubmed.ncbi.nlm.nih.gov
7. Elsayed HH, Ali I, Abdel-Gayed M, Warda AM, Moharram AA. The efficacy of oral corticosteroids for treatment of Tietze syndrome: a pragmatic randomized controlled trial. The Journal of Clinical Pharmacy and Therapeutics, 2022;47(12):2279–2286. pubmed.ncbi.nlm.nih.gov
8. Senturk E, Sahin E, Serter S. Prolotherapy: an effective therapy for Tietze syndrome. Journal of Back and Musculoskeletal Rehabilitation, 2017;30(5):975–978. pubmed.ncbi.nlm.nih.gov
9. de Carvalho JF. Tietze's syndrome. Mediterranean Journal of Rheumatology, 2022;33(4):467–468. pubmed.ncbi.nlm.nih.gov
10. Silva PGMBE, Berwanger O, Santos ESD, et al. One year follow-up assessment of patients included in the Brazilian Registry of Acute Coronary Syndromes (ACCEPT). Arquivos Brasileiros de Cardiologia, 2020;114(6):995–1003. pubmed.ncbi.nlm.nih.gov
11. Pereira AMB, Rosa AA, Flávio-Reis VHP, et al. Outcomes and risk profiles of acute coronary syndrome patients treated with percutaneous coronary intervention: insights from a Brazilian tertiary care center. Catheterization and Cardiovascular Interventions, 2026;107(3):703–710. pubmed.ncbi.nlm.nih.gov

Lineage, no numbers carried: Tietze A. Über eine eigenartige Erkrankung der Rippenknorpel. Berliner Klinische Wochenschrift, 1921 — the swelling that named the twin.